Preclinical studies of oxaliplatin in combination chemotherapy

Therapeutic innovation in oncology often requires the optimization of combi nations with active drugs based on in vitro and in vivo data. This is exemp lified by oxaliplatin for which several preclinical studies of combinations have been realized Oxaliplatin has been combined with 5-fluoro-uracile, ge mcitabine, topoisomerase I inhibitors, taxanes demonstrating synergy or add itivity. Synergistic and additive effects are often due to the optimization in the use of distinct mechanism of action or resistance and might be asso ciated with no overlapping toxicity when combined in clinical trials.